|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
MXPA05002887A
(es)
*
|
2002-09-16 |
2005-05-27 |
Glaxo Group Ltd |
Compuestos de pirazolo[3,4-b]piridina, y su uso como inhibidores de fosfodiesterasa.
|
|
GB0230045D0
(en)
|
2002-12-23 |
2003-01-29 |
Glaxo Group Ltd |
Compounds
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
CA2557004A1
(en)
*
|
2003-12-19 |
2005-06-30 |
Glaxo Group Limited |
Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors
|
|
JP2007529464A
(ja)
*
|
2004-03-16 |
2007-10-25 |
グラクソ グループ リミテッド |
ビラゾロ［３，４−ｂ］ピリジン化合物及びＰＤＥ４阻害剤としてのその使用
|
|
GB0405933D0
(en)
*
|
2004-03-16 |
2004-04-21 |
Glaxo Group Ltd |
Compounds
|
|
WO2005118543A1
(ja)
*
|
2004-06-03 |
2005-12-15 |
Ono Pharmaceutical Co., Ltd. |
キナーゼ阻害薬およびその用途
|
|
WO2006072599A2
(en)
|
2005-01-10 |
2006-07-13 |
Glaxo Group Limited |
Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions
|
|
CN101248050B
(zh)
|
2005-06-06 |
2013-07-17 |
武田药品工业株式会社 |
有机化合物
|
|
AU2006264170A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Ambrilia Biopharma Inc. |
Pyrazolo[3,4-b]pyridin-2-yl)-benzoic acid derivatives as HIV integrase inhibitors
|
|
US20090221644A1
(en)
*
|
2005-06-30 |
2009-09-03 |
Stuart Edward Bradley |
Gpcr Agonists
|
|
WO2007003960A1
(en)
*
|
2005-06-30 |
2007-01-11 |
Prosidion Limited |
Gpcr agonists
|
|
US20100022571A1
(en)
|
2005-09-16 |
2010-01-28 |
Palle Venkata P |
Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
US20090131431A1
(en)
*
|
2005-09-29 |
2009-05-21 |
Christopher David Edlin |
Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
|
|
PE20071068A1
(es)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
|
|
JP2009529047A
(ja)
|
2006-03-07 |
2009-08-13 |
アレイ バイオファーマ、インコーポレイテッド |
ヘテロ二環系ピラゾール化合物およびその使用
|
|
AR060536A1
(es)
|
2006-04-20 |
2008-06-25 |
Glaxo Group Ltd |
Agonista del receptor de glucocorticoides y composiciones farmaceuticas
|
|
CA2652840C
(en)
|
2006-05-24 |
2014-09-09 |
Boehringer Ingelheim International Gmbh |
2-piperazino-6-chloro-pteridines as pde4-inhibitors for the treatment of inflammatory diseases
|
|
EP2023729B1
(en)
|
2006-06-06 |
2016-05-04 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
GB0614570D0
(en)
*
|
2006-07-21 |
2006-08-30 |
Glaxo Group Ltd |
Compounds
|
|
HRP20110434T1
(hr)
|
2006-08-01 |
2011-08-31 |
Glaxo Group Limited |
Spojevi pirazolo[3,4-b]piridina i njihova upotreba kao inhibitora pde4
|
|
US8492378B2
(en)
|
2006-08-03 |
2013-07-23 |
Takeda Pharmaceutical Company Limited |
GSK-3β inhibitor
|
|
JP5837278B2
(ja)
|
2006-12-05 |
2015-12-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
新規使用
|
|
MX2009009793A
(es)
|
2007-03-14 |
2009-10-16 |
Ranbaxy Lab Ltd |
Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
|
|
WO2008111009A1
(en)
*
|
2007-03-14 |
2008-09-18 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
|
|
PE20081889A1
(es)
|
2007-03-23 |
2009-03-05 |
Smithkline Beecham Corp |
Indol carboxamidas como inhibidores de ikk2
|
|
CA2697551C
(en)
|
2007-09-20 |
2013-03-12 |
Irm Llc |
Piperidine derivatives as modulators of gpr119 activity
|
|
WO2009055033A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Amgen Inc. |
Pyrazolo-pyridinone derivatives and methods of use
|
|
ES2588238T3
(es)
*
|
2007-12-06 |
2016-10-31 |
Intra-Cellular Therapies, Inc. |
Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
|
|
PE20091563A1
(es)
*
|
2008-02-06 |
2009-11-05 |
Glaxo Group Ltd |
Farmacoforos duales - antagonistas muscarinicos de pde4
|
|
PE20091552A1
(es)
|
2008-02-06 |
2009-10-25 |
Glaxo Group Ltd |
Farmacoforos duales - antagonistas muscarinicos de pde4
|
|
WO2009100169A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Glaxo Group Limited |
Dual pharmacophores - pde4-muscarinic antagonistics
|
|
EP2249830A4
(en)
*
|
2008-02-06 |
2012-07-18 |
Glaxo Group Ltd |
DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY
|
|
AR070564A1
(es)
|
2008-02-06 |
2010-04-21 |
Glaxo Group Ltd |
Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100598A1
(en)
*
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
US20110160249A1
(en)
|
2008-05-23 |
2011-06-30 |
Schaab Kevin Murray |
5-lipoxygenase-activating protein inhibitor
|
|
JP5502858B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
|
|
WO2010002209A2
(en)
*
|
2008-07-02 |
2010-01-07 |
Amorepacific Corporation |
Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same
|
|
CA2735956A1
(en)
*
|
2008-09-19 |
2010-04-29 |
Ranbaxy Laboratories Limited |
Phosphodiestarase inhibitors
|
|
WO2010065153A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
MX2011005934A
(es)
|
2008-12-06 |
2011-12-16 |
Intra Cellular Therapies Inc |
Compuestos organicos.
|
|
AU2009322901A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
EA201170768A1
(ru)
|
2008-12-06 |
2012-05-30 |
Интра-Селлулар Терапиз, Инк. |
Органические соединения
|
|
WO2010065151A1
(en)
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
CA2740388A1
(en)
*
|
2008-12-06 |
2010-06-10 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
RU2494976C2
(ru)
|
2009-02-24 |
2013-10-10 |
Бойдел Вействотер Текнолоджиз Инк. |
Устройство и способ для обработки сточных вод
|
|
ES2542551T3
(es)
|
2009-03-09 |
2015-08-06 |
Glaxo Group Limited |
4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
|
|
JP2012520257A
(ja)
|
2009-03-10 |
2012-09-06 |
グラクソ グループ リミテッド |
Ｉｋｋ２阻害剤としてのインドール誘導体
|
|
JP2012520845A
(ja)
|
2009-03-17 |
2012-09-10 |
グラクソ グループ リミテッド |
Ｉｔｋ阻害剤として使用されるピリミジン誘導体
|
|
WO2010107952A2
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP2012520685A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたＧＡＴＡ結合タンパク質３（ＧＡＴＡ３）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
CA2755773A1
(en)
|
2009-03-19 |
2010-09-23 |
Merck Sharp & Dohme Corp. |
Rna interference mediated inhibition of btb and cnc homology 1, basic leucine zipper transcription factor 1 (bach 1) gene expression using short interfering nucleic acid (sina)
|
|
JP2012520686A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子６（ＳＴＡＴ６）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
JP2012521763A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いたシグナル伝達性転写因子１（ＳＴＡＴ１）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
KR20110138223A
(ko)
|
2009-03-27 |
2011-12-26 |
머크 샤프 앤드 돔 코포레이션 |
짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
|
|
WO2010111464A1
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
JP2012521764A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いた胸腺間質性リンパ球新生因子（ＴＳＬＰ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
US20120004281A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp |
RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
UY32571A
(es)
|
2009-04-24 |
2010-11-30 |
Glaxo Group Ltd |
Compuestos derivados de pirazol amida
|
|
EP2421834A1
(en)
|
2009-04-24 |
2012-02-29 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
|
TWI516487B
(zh)
|
2009-04-30 |
2016-01-11 |
葛蘭素集團有限公司 |
新穎化合物、其醫藥組合物及作為激酶活性抑制劑之用途
|
|
EP2434895A4
(en)
|
2009-05-13 |
2013-08-07 |
Intra Cellular Therapies Inc |
ORGANIC CONNECTIONS
|
|
EP2507226A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Novel compounds
|
|
WO2011067366A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
|
US20120245171A1
(en)
|
2009-12-03 |
2012-09-27 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of pi3 kinases
|
|
EP2514749B1
(en)
*
|
2009-12-15 |
2015-02-25 |
Shionogi & Co., Ltd. |
Oxadiazole derivative having endothelial lipase inhibitory activity
|
|
WO2011107394A1
(en)
|
2010-03-01 |
2011-09-09 |
Glaxo Group Limited |
Treatment of anxiety disorders
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
TW201209054A
(en)
|
2010-05-28 |
2012-03-01 |
Prosidion Ltd |
Novel compounds
|
|
TW201206937A
(en)
|
2010-05-31 |
2012-02-16 |
Intra Cellular Therapies Inc |
Organic compounds
|
|
JP5894148B2
(ja)
|
2010-05-31 |
2016-03-23 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
有機化合物
|
|
US9763948B2
(en)
|
2010-05-31 |
2017-09-19 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitory compounds and methods
|
|
US9434730B2
(en)
|
2010-05-31 |
2016-09-06 |
Intra-Cellular Therapies, Inc. |
PDE1 inhibitor compounds
|
|
US9326987B2
(en)
|
2010-09-08 |
2016-05-03 |
Glaxo Group Limited |
Indazole derivatives for use in the treatment of influenza virus infection
|
|
PL2614058T3
(pl)
|
2010-09-08 |
2015-12-31 |
Glaxosmithkline Ip Dev Ltd |
Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
WO2012052458A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, immune and inflammatory conditions
|
|
US9149462B2
(en)
|
2010-10-21 |
2015-10-06 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
JP2014507458A
(ja)
|
2011-03-11 |
2014-03-27 |
グラクソ グループ リミテッド |
Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
JP6051210B2
(ja)
|
2011-06-10 |
2016-12-27 |
イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． |
有機化合物
|
|
WO2013117693A1
(en)
|
2012-02-10 |
2013-08-15 |
Glaxosmithkline Intellectual Property Development Limited |
Pde4 inhibitor for treating huntington's disease
|
|
PE20142258A1
(es)
|
2012-04-25 |
2015-01-15 |
Takeda Pharmaceutical |
Compuesto heterociclico nitrogenado
|
|
WO2014010732A1
(ja)
|
2012-07-13 |
2014-01-16 |
武田薬品工業株式会社 |
複素環化合物
|
|
WO2014127331A1
(en)
|
2013-02-17 |
2014-08-21 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
|
EP2975031A4
(en)
|
2013-03-14 |
2017-04-19 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
EP2968338B1
(en)
|
2013-03-15 |
2019-01-09 |
Intra-Cellular Therapies, Inc. |
Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
|
|
ES2836129T3
(es)
|
2013-03-15 |
2021-06-24 |
Intra Cellular Therapies Inc |
Compuestos orgánicos
|
|
EP3018126A4
(en)
|
2013-07-03 |
2016-12-07 |
Takeda Pharmaceuticals Co |
HETEROCYCLIC CONNECTION
|
|
WO2015002230A1
(ja)
|
2013-07-03 |
2015-01-08 |
武田薬品工業株式会社 |
アミド化合物
|
|
WO2015012328A1
(ja)
|
2013-07-24 |
2015-01-29 |
武田薬品工業株式会社 |
複素環化合物
|
|
CA2925064A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
CA2923995A1
(en)
|
2013-10-17 |
2015-04-23 |
Glaxosmithkline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
WO2015173701A2
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
|
ES2732442T3
(es)
|
2014-06-20 |
2019-11-22 |
Intra Cellular Therapies Inc |
Compuestos orgánicos
|
|
US9546175B2
(en)
|
2014-08-07 |
2017-01-17 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
|
TWI686394B
(zh)
|
2014-08-07 |
2020-03-01 |
美商內胞醫療公司 |
有機化合物
|
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
|
WO2016044667A1
(en)
|
2014-09-17 |
2016-03-24 |
Intra-Cellular Therapies, Inc. |
Compounds and methods
|
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
EP3436083A4
(en)
|
2016-03-28 |
2019-11-27 |
Intra-Cellular Therapies, Inc. |
NOVEL COMPOSITIONS AND METHOD
|
|
US10034861B2
(en)
|
2016-07-04 |
2018-07-31 |
H. Lundbeck A/S |
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
|
|
US20190161480A1
(en)
|
2016-08-08 |
2019-05-30 |
Glaxosmithkline Intellectual Property Development Limited |
Chemical Compounds
|
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ－セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
WO2019104285A1
(en)
*
|
2017-11-27 |
2019-05-31 |
Dart Neuroscience, Llc |
Substituted furanopyrimidine compounds as pde1 inhibitors
|
|
HRP20211784T1
(hr)
|
2017-12-14 |
2022-02-18 |
H. Lundbeck A/S |
Kombinacijski tretmani koji se sastoje od primjene 1h-pirazolo[4,3-b]piridina
|
|
AR113926A1
(es)
|
2017-12-14 |
2020-07-01 |
H Lundbeck As |
Derivados de 1h-pirazolo[4,3-b]piridinas
|
|
US10766893B2
(en)
*
|
2017-12-20 |
2020-09-08 |
H. Lundbeck A/S |
1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
|
|
CN117447475A
(zh)
|
2017-12-20 |
2024-01-26 |
H.隆德贝克有限公司 |
作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
|
|
MX2020007383A
(es)
|
2018-01-12 |
2020-10-12 |
Aurigene Discovery Tech Ltd |
Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
|
|
US11839614B2
(en)
|
2018-01-31 |
2023-12-12 |
Intra-Cellular Therapies, Inc. |
Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
|
|
JP7612672B2
(ja)
|
2019-09-03 |
2025-01-14 |
イントラ－セルラー・セラピーズ・インコーポレイテッド |
新規化合物
|
|
US12364695B2
(en)
|
2020-06-02 |
2025-07-22 |
Intra-Cellular Therapies, Inc. |
Methods of treating inflammatory disease
|
|
WO2023049199A1
(en)
*
|
2021-09-24 |
2023-03-30 |
Zeno Management, Inc. |
Azole compounds
|
|
EP4644373A1
(en)
*
|
2022-12-28 |
2025-11-05 |
Nippon Soda Co., Ltd. |
Hydrazide compound and agricultural/horticultural bactericidal agent
|